Intervention Review

Molindone for schizophrenia and severe mental illness

  1. Anne-Marie Bagnall1,*,
  2. Mark Fenton2,
  3. Jos Kleijnen3,
  4. Ruth Lewis4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 16 JUL 2008

Assessed as up-to-date: 13 NOV 2006

DOI: 10.1002/14651858.CD002083.pub2

Database Title

Additional Information

How to Cite

Bagnall AM, Fenton M, Kleijnen J, Lewis R. Molindone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002083. DOI: 10.1002/14651858.CD002083.pub2.

Author Information

  1. 1

    Leeds Metropolitan University, Faculty of Health, Leeds, UK

  2. 2

    James Lind Initiative, Database of Uncertainties about the Effects of Treatments (DUETs), Oxford, UK

  3. 3

    Kleijnen Systematic Reviews Ltd, York, UK

  4. 4

    Cardiff University, Department of General Practice, Wrexham, UK

*Anne-Marie Bagnall, Faculty of Health, Leeds Metropolitan University, Calverley Street, Leeds, LS1 3HE, UK. A.Bagnall@leedsmet.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 16 JUL 2008

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (58K)Standard (340K)Full (561K)

  1. Current Version

    Molindone for schizophrenia and severe mental illness

    Anne-Marie Bagnall, Mark Fenton, Jos Kleijnen and Ruth Lewis

    Article first published online: 16 JUL 2008 | DOI: 10.1002/14651858.CD002083.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Molindone for schizophrenia and severe mental illness

    A-M Bagnall, M Fenton, R Lewis, ML Leitner and J Kleijnen

    Article first published online: 18 OCT 2006 | DOI: 10.1002/14651858.CD002083

View Full Article (HTML) Summary (58K)Standard (340K)Full (561K)